IONIS-FXIRx: Ph II data

A double-blind, Canadian Phase II trial in 43 patients with ESRD receiving hemodialysis showed that 200 and 300 mg doses of subcutaneous IONIS-FXIRx dosed twice weekly for 2 weeks and then once weekly...